STAT+: Sickle cell gene therapies could be cost-effective even if priced as high as $1.9 million
The pending arrival of the treatments is causing a degree of trepidation, because gene therapies are so costly.
As the U.S. health care system prepares for expensive gene therapies, a preliminary analysis suggests that a pair of forthcoming treatments for sickle cell disease would be cost-effective if priced as high as $1.9 million, depending upon certain variables.
The medications — one is being developed by Bluebird Bio and the other by a partnership between Vertex Pharmaceuticals and CRISPR Therapeutics — have not yet been approved by the Food and Drug Administration. As a result, pricing has not been disclosed, but analyst estimates have suggested the treatments may be priced at roughly $2 million.
What's Your Reaction?
